Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. (NASDAQ: OFIX) is a global medical technology company headquartered in Lewisville, Texas, with a focus on musculoskeletal care. The Orthofix news stream highlights developments across its spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including updates related to the 7D FLASH™ Navigation System.
Investors and healthcare professionals following Orthofix news can review regular earnings announcements, where the company reports net sales and segment performance for Bone Growth Therapies, Spinal Implants, Biologics and Enabling Technologies, Global Spine and Global Orthopedics. These releases often include commentary on trends in U.S. Spine Fixation, bone growth therapy performance, and the progress of its orthopedics business focused on limb reconstruction.
News coverage also features regulatory and product milestones, such as FDA 510(k) clearance and CE Mark for the TrueLok™ Elevate Transverse Bone Transport System and the global commercial launch of TrueLok Elevate. Orthofix uses these announcements to describe how TrueLok Elevate fits into its TrueLok family of multiplanar external fixators and supports limb preservation and diabetic wound-related treatment needs.
In addition, Orthofix issues releases about upcoming investor conference appearances and the timing of quarterly financial results and conference calls. For anyone tracking OFIX, this news page provides a centralized view of the company’s public communications on financial performance, product launches, regulatory clearances and investor events.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Orthofix Medical Inc. (NASDAQ:OFIX) will release its first quarter 2023 financial results on May 9, 2023, after market close. A conference call to discuss these results will take place at 4:30 p.m. ET on the same day, with access details available for interested parties. The newly merged Orthofix-SeaSpine organization is recognized as a leader in the global spine and orthopedics sector, offering a diverse range of products distributed across approximately 68 countries. The company is headquartered in Lewisville, Texas, and maintains a focus on innovation in spine and biologics products, with significant presence across multiple locations including California and Europe.
Orthofix Medical Inc (NASDAQ: OFIX) announced the full commercial launch of two innovative access retractor systems, the Lattus™ Lateral Access System and the Fathom™ Pedicle-Based Retractor System, aimed at enhancing minimally invasive spine (MIS) surgeries, targeting a market valued at approximately $1.8 billion.
The Lattus system emphasizes user-friendliness and versatility, improving access and procedural efficiency for spine surgeries. Meanwhile, the Fathom system allows for precise control over blade adjustments, enhancing surgical outcomes. Both systems are designed to integrate seamlessly with Orthofix's existing products, demonstrating the company's commitment to delivering comprehensive solutions in the operating room.
Orthofix Medical Inc (NASDAQ:OFIX) announced that its Fitbone™ TAA intramedullary limb-lengthening system has surpassed 5,000 implants, with over 20 years of clinical safety and efficacy evidence. This system addresses limb length discrepancies through a minimally invasive procedure. The Fitbone system is available in the U.S. under FDA 510(k) clearance and holds a pediatric indication, making it unique in the market. Orthofix is positioned as a leader in internal and external fixation solutions for limb reconstruction, targeting innovative treatment options for patients with deformities.
The merger of Orthofix Medical and SeaSpine Holdings became effective on January 5, 2023. For Q4 2022, Orthofix reported net sales of $122.2 million, a 2% decline year-over-year, with Bone Growth Therapies growing by 3%. SeaSpine's net sales rose 14% to $63.4 million, buoyed by a strong performance in U.S. Spinal Implants and Orthobiologics, which experienced growth of 23% and 20%, respectively. The merger aims to create synergies, although initial revenue guidance for 2023 reflects minimal impact from these synergies. Orthofix's net loss for Q4 was $(7.1) million, while SeaSpine's net loss stood at $(19.0) million.
Orthofix Medical Inc. (NASDAQ:OFIX) announced an Analyst Teach-In Meeting in Lewisville, TX, on March 13, 2023, from 2:30 to approximately 6:30 p.m. CT. The C-Suite management team will detail the product portfolio and commercial strategy following the merger with SeaSpine. The event has limited in-person attendance, but a live and archived webcast will be available on the company's investor page. The merged entity offers a broad range of products in biologics, spinal hardware, and orthopedic solutions, operating in around 68 countries globally, with a focus on innovation and education.
FAQ
What is the current stock price of Orthofix Med (OFIX)?
What is the market cap of Orthofix Med (OFIX)?
